Abbott Laboratories loses bid to halt Glucerna class action
By Diana Novak Jones
June 6 (Reuters) -Litigation claiming that Abbott Laboratories is marketing Glucerna shakes and nutritional powders with harmful ingredients can move forward, a California federal judge said Wednesday.
U.S. District Judge P. Casey Pitts in San Jose largely rejected Abbott’s motion to dismiss the proposed class action, ruling that the consumers had provided enough evidence at this stage to support their claims that Glucerna, which says on its label that it is “scientifically designed for people with diabetes," contains sucralose and other additives that some studies show have dangerous health effects.
Pitts granted Abbott’s motion to dismiss the consumers’ request for an injunction requiring Abbott to amend the labeling on the Glucerna products, saying customers concerned about the additives can check the ingredients list to see if the products contain sucralose going forward.
Representatives for Abbott Laboratories did not immediately respond to requests for comment on the ruling.
Bahar Sodaify, an attorney for the consumers, said in a statement that now Abbott "will have to answer why it elected to center Glucerna’s brand identity and product labeling on diabetes care while using ingredients that are known to deregulate blood sugar and are just not suitable for diabetics."
California resident Steven Prescott sued Abbott in August, alleging that the labels on the Glucerna products said they could help regulate blood sugar in diabetics and people with similar conditions. The lawsuit claims that the products are sweetened with sugar replacement sucralose, which is approved by the U.S. Food and Drug Administration for use in food but can deregulate blood sugar, kill cells in the pancreas that release insulin and cause cells to become resistant to insulin.
Prescott, who sued under California consumer protection laws, said he would not have purchased the products had he known they wouldn’t work as advertised. Prescott is seeking to represent a class of California consumers who purchased the products.
Abbott has argued that the labeling on the Glucerna products is not misleading and that the products are meant to be a snack or meal replacement that helps with blood sugar regulation as compared with high glycemic carbohydrates. The company has also criticized the studies on sucralose Prescott relies on, saying they do not support a link between the sweetener and the health problems he alleges.
In its motion to dismiss, Abbott pointed to the shakes’ side label, which says the product is designed to “help minimize blood sugar spikes” in diabetics as compared with high glycemic carbohydrates.
But Pitts said at this stage that he couldn’t conclude that a consumer would understand that the side label limits the labeling on the front of the bottle as much as Abbott suggests.
The case is Prescott et al v. Abbott Laboratories, case number 5:23-cv-04348 in the U.S. District Court for the Northern District of California
For plaintiffs: Shireen Clarkson, Bahar Sodaify and Alan Gudino of Clarkson Law Firm
For Abbott: Matthew Powers of O’Melveny & Myers, William Cavanaugh Jr and Jane Metcalf of Patterson Belknap Webb & Tyler
Asset collegati
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.
